Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Zevalin | Ibritumomab tiuxetan | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Demylocan | decitabine | Myelodysplastic Syndromes | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Talzenna | talazoparib | Breast cancer | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Zolinza | vorinostat | Cutaneous T-cell lymphoma | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Emgality | galcanezumab | Episodic cluster headache | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Nucala | mepolizumab | Eosinophilic granulomatosis with polyangiitis | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Xarelto | Rivaroxaban (granules for oral suspension) | Venous Thromboembolic Events | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : April 18, 2024